Vaccines, Blood & Biologics
-
XYNTHA
STN: BL 125264
Proper Name: Antihemophilic Factor (Recombinant), Plasma/Albumin Free
Tradename: XYNTHA
Manufacturer: Wyeth Pharmaceuticals, Inc, License #0003
Indication:
- For control and prevention of bleeding episodes and for surgical prophylaxis in patients with hemophilia A
-
Supporting Documents
April 12, 2012 Approval Letter - XYNTHA
To demonstrate the safety and efficacy of Xyntha for surgical prophylaxis in patients with hemophilia A.February 21, 2008 Approval Letter - XYNTHA March 7, 2008 Corrected Approval Letter - XYNTHA Approval History, Letters, Reviews and Related Documents - XYNTHA
-
-
Related Information
FDA Online Label Repository
Search this database for drug labeling and other information. The content has not been altered or verified by the FDA and may not be the labeling on currently distributed products or identical to the labeling that is approved.FDA Licenses New Hemophilia Treatment [ARCHIVED]
Press Release - February 21, 2008
-
-
-







